Skip to main content
. 2023 Dec 15;12(24):22325–22332. doi: 10.1002/cam4.6788

FIGURE 3.

FIGURE 3

(A) Adjusted percentage of men treated for prostate cancer undergoing diagnostic testing within 1 year of diagnosis by practice equity acquisition (not acquired vs. acquired) over time, relative to the acquisition period (pre, post). Private equity did not affect the use of diagnostic testing in those who were treated (difference‐in‐differences −3.7%, p = 0.30). (B) Adjusted percentage of untreated men with prostate cancer undergoing diagnostic testing within 1 year of diagnosis by practice equity acquisition (not acquired vs. acquired) over time, relative to the acquisition period (pre, post). Acquisition did not affect the use of diagnostic testing in untreated men (difference‐in‐differences −5.0%, p = 0.82) treated.